Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022)
Definium Therapeutics (DFTX) posted quarterly Tax Provisions of $224000.0 for Q4 2022, up 101.13% year-over-year from $111369.4 in Q4 2021, and up 101.13% quarter-over-quarter from -$19.8 million in Q4 2021.
Powered by 
Analysis
Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022) Analysis & Trends
Definium Therapeutics (DFTX) has reported Tax Provisions for 2 consecutive years, with $224000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Tax Provisions rose 101.13% year-over-year to $224000.0; the TTM figure through Dec 2022 stood at -$19.6 million (changed N/A YoY), while the FY2022 annual figure was $224000.0, up 101.13% from the prior year.
- Tax Provisions advanced to $224000.0 in Q4 2022 per DFTX's latest filing, from -$19.8 million in the prior quarter.
- Across five years, Tax Provisions topped out at $224000.0 in Q4 2022 and bottomed at -$19.8 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | - |